Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - Scienture Holdings, Inc. (0001382574) (Issuer)
4 - Scienture Holdings, Inc. (0001382574) (Issuer)
Commercial availability expected in August as the Company advances the rollout of the highest-dose FDA-approved naloxone hydrochloride nasal spray U.S. naloxone market totals ~$144 million in annual sales and ~9.8 million units annually, represents significant commercial opportunity for REZENOPY™ COMMACK, NY, July 09, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) ("Scienture"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that i
Broader pharmacy access, channel expansion, and payer coverage position Arbli™ for increased prescription volume and revenue growth COMMACK, NY, June 18, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced significant progress in the commercialization of Arbli™ (losartan potassium oral suspension), including expanded payor coverage, broader pharmacy access, new channel partnerships, and on
Commercial Launch Planned for Mid-July; 5,000+ Healthcare Facilities Reached Through GPO Agreements, Covering ~60% of Institutional GPO Market U.S. naloxone market totals ~$144 million in annual sales and ~9.8 million units annually, represents significant commercial opportunity for REZENOPY™ COMMACK, NY, June 09, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) ("Scienture"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that REZEN
8-K - Scienture Holdings, Inc. (0001382574) (Filer)
8-K - Scienture Holdings, Inc. (0001382574) (Filer)
10-Q - Scienture Holdings, Inc. (0001382574) (Filer)
TAMPA, FL, May 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) (the "Company"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that Suren Ajjarapu, who has served as Chief Executive Officer (CEO) and Chairman of the Board of Directors (BOD), has stepped down from his roles with the Company, with those positions being assumed by the existing, experienced management team of Dr. Shankar Hariharan and Dr. Narasimhan Mani. Shankar Hariharan, P